{"protocolSection":{"identificationModule":{"nctId":"NCT03211221","orgStudyIdInfo":{"id":"Pallanti"},"briefTitle":"rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder.","officialTitle":"rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder: a Multicenter, Double-blind, Controlled Trial."},"descriptionModule":{"briefSummary":"The aim of this study is to investigate the effectiveness of low-frequency (1Hz) rTMS (repetitive transcranial magnetic stimulation) over the pre-SMA (pre-supplementary motor area) in a sample of treatment-resistant OCD patients in a multicenter, controlled design.","detailedDescription":"N consecutive treatment-resistant OCD outpatients, fulfilling all the inclusion criteria, will be recruited by each center involved in the study.\n\nTo be included in the study all the patients must be aged between 18 and 65 yy and have to meet DSM-5 criteria for OCD with a Y-BOCS total score \\> or = 20 and a history of treatment-resistant OCD, established by a trained psychiatrist with extensive expertise in the OCD field. Treatment-resistance is defined as non-response (less than 25% reduction of the Y-BOCS score) after at least one SRIs trials (clomipramine, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, escitalopram) at the maximum tolerable dose for at least 12 weeks. Potential patients with any of the following conditions will be excluded: 1) any additional current psychiatric comorbidity, except for mild depressive and anxious symptoms or tics; 2) a lifetime DSM-5 diagnosis of schizophrenia or other psychotic syndromes, substance dependence or substance abuse, including alcohol, bipolar I or II disorder, mental disorder due to a general medical condition; 3) serious suicide risk; 4) episodic OCD; 5) illness duration less than two years; 6) hospitalization in the last 6 months; 7) refractory OCD (defined as non response to two SRIs trials, one antidopaminergic augmentation and at least one CBT with ERP trial); 8) patient who did not response to a previous ECT trial; 9) the inability to receive rTMS because of metallic implants, or history of seizures (personal or family history of seizure in first degree relatives); 10) any major medical disease; 11) pregnancy or nursing of an infant; 12) the inability or refusal to provide written informed consent.\n\nNo psychotherapy and/or pharmacological treatments changes will be allowed during the study period. Pharmacologically treated patients should be on constant medications for at least 6 weeks before entering the study.\n\nFemale patients included in the study will not be required to adopt contraceptive measures.\n\nPatients with prior TMS exposure will be excluded in order to reduce the risk of unblinding.\n\nDesign of the Study Patients will be randomized to receive 15 sessions of active rTMS or sham rTMS over the bilateral pre-SMA with a 1:1: ratio. After the randomized phase, all patients will undergo a 4 weeks washout phase. During the wash out phase each patients will be re-assessed every two weeks in order to detect long-lasting rTMS effects. At the end of the wash phase each patient will be classified as responder, partial responder or non-responder. After the washout phase responder patients will enter a follow-up phase up to 12 months while partial responders or non-responders in both the active and sham rTMS groups, will undergo an open phase of 15 sessions of active rTMS over the bilateral pre-SMA. After the open rTMS phase, all patients will undergo a 4 weeks washout phase. During the wash out phase each patients will be re-assessed every two weeks in order to detect long-lasting rTMS effects. Responder patients will then continue in the follow-up phase, while non-responder or partial responders will leave the study.\n\nPartial responders and non-responders after the randomized phase who will choose not to go into the open phase will end the study.\n\nStudy flow-chart\n\nActive rTMS procedures Active rTMS will be administered with Magventure, Medtronic, Magandmore, Magstim, Neuronetics TMS devices using a vacuum cooled 70-mm figure-of-eight coil. Stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System (Choi et al. 2006). Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.\n\nSham rTMS procedures Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp (Lisamby et al., 2001). This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS (Lisanby et al., 2001).\n\nMotor Threshold Resting MT will be defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 mV in peak-to-peak amplitude) in a resting target muscle (abductor pollicis brevis) in 5/10 trials using single-pulse TMS administered to the contralateral primary motor cortex. The motor threshold will be re-assessed every session before starting the rTMS treatment.\n\nSide-effect ratings Before and after each session patients were asked by a blinded assessor a series of questions in a structured form in order to rate TMS side-effects. For this purpose the investigators will use the Monitoring of Side Effects Scale (MOSES).\n\nClinical assessment After a screening visit, the patients fulfilling the inclusion criteria will be assessed before entry the study with a comprehensive clinical interview (age, sex, education, OCD onset, OCD subtype, duration of the illness, history of past or current TICs, previews pharmacological and psychotherapeutic treatments, treatment resistance, lifetime comorbidities) and a psychometric assessment including the following tools: The SCID-5 CV (Structured Clinical Interview for DSM-5 Disorders-Clinician Version), the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Y-BOCS-SC (symptoms checklist) (Goodman et al., 1989a,b), the Hamilton Anxiety rating Scale (HAM-A) (Hamilton, 1959), the Hamilton Depression Rating Scale (HAM-D-17 itemes) (Hamilton, 1967) and the Clinical Global Impression Scale (CGI) (Guy, 2000).\n\nBefore starting the rTMS procedures and after 10 and 15 sessions all patients will be assessed by a blinded assessor with the following psychometric scale: Y-BOCS, HAM-D, HAM-A, CGI-S and the CGI-I. During the washput phase each patient will be re-assessed at week 2 and 4 with the Y-BOCS, HAM-D, HAM-A, CGI-S and the CGI-I.\n\nPatients entering the open phase will be assessed after 10 and 15 sessions and at week 2 and 4 of the second washout phase with the Y-BOCS, HAM-D, HAM-A, CGI-S and the CGI-I.\n\nStandard criteria for the treatment outcome will be included in the trial: response (\\>35% improvement in baseline Y-BOCS scores and a CGI-I of 1 or 2), partial response (≥ 25% improvement in baseline Y-BOCS scores), and non-response (\\<25% improvement in baseline Y-BOCS scores).\n\nThe end-point assessment will be repeated at 3, 6, 9 and 12 months follow-up visits after the last rTMS session in an open design."},"conditionsModule":{"conditions":["Obsessive-Compulsive Disorder"]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* age between 18 and 65 yy\n* DSM-5 criteria for OCD\n* Y-BOCS total score \\> or = 20\n* History of treatment-resistant OCD, established by a trained psychiatrist with extensive expertise in the OCD field. Treatment-resistance is defined as non-response (less than 25% reduction of the Y-BOCS score) after at least one SRIs trials (clomipramine, fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, escitalopram) at the maximum tolerable dose for at least 12 weeks.\n\nExclusion Criteria:\n\n* any additional current psychiatric comorbidity, except for mild depressive and anxious symptoms or tics;\n* a lifetime DSM-5 diagnosis of schizophrenia or other psychotic syndromes, substance dependence or substance abuse, including alcohol, bipolar I or II disorder, mental disorder due to a general medical condition;\n* serious suicide risk;\n* episodic OCD;\n* illness duration less than two years\n* hospitalization in the last 6 months;\n* refractory OCD (defined as non response to two SRIs trials, one antidopaminergic augmentation and at least one CBT with ERP trial);\n* patient who did not response to a previous ECT trial;\n* the inability to receive rTMS because of metallic implants, or history of seizures (personal or family history of seizure in first degree relatives);\n* any major medical disease;\n* pregnancy or nursing of an infant;\n* the inability or refusal to provide written informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]}}}